Hrt Financial LP Contrafect Corp Transaction History

Hrt Financial LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.09 - $0.19 $6,223 - $13,137	69,145 New	69,145 $6,000
Q4 2021 Feb 14, 2022	SELL	$2.47 - $4.14 $129,771 - $217,511	-52,539 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.19 - $4.43 $52,236 - $72,541	-16,375 Reduced 23.76%	52,539 $212,000
Q2 2021 Aug 16, 2021	BUY	$3.58 - $4.9 $246,712 - $337,678	68,914 New	68,914 $303,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.